TD Cowen's USD 9.00 target leaves Maravai LifeSciences stock 32.55 percent below target

Published on 10/17/2026 at 22:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue was USD 51.44 million in second quarter 2026. Maravai LifeSciences stock costs USD 6.79 on October 16, 2026, down 3.96 percent on Nasdaq.

Analyst view and upcoming results

TD Cowen's USD 9.00 target left 32.55 percent between the October 5, 2026 target and the stock price.
Second-quarter 2026 revenue reached USD 51.44 million.
Maravai LifeSciences stock last traded at USD 6.79 on October 16, 2026, down 3.96 percent on Nasdaq.
Maravai LifeSciences plans its third-quarter 2026 earnings call for November 4, 2026.

MRVI, US56600D1072, Illustration mit AI erstellt.

TD Cowen's USD 9.00 target leaves Maravai LifeSciences stock 32.55 percent below the target, based on the latest USD 6.79 Nasdaq price. Markets Insider reported on October 5, 2026 that TD Cowen initiated coverage with a Buy rating and the USD 9.00 target. Maravai LifeSciences last traded at USD 6.79 on October 16, 2026 at 4:00 p.m. ET, down 3.96 percent on Nasdaq on the day.

Revenue reached USD 51.44 million

Maravai LifeSciences reported USD 51.44 million in revenue for the second quarter of 2026, ended June 30, 2026. The company generated a net loss attributable to common shareholders of USD 12.42 million and diluted earnings per share of minus USD 0.08 in that period. Operating cash flow was USD 3.99 million.

Stock position and trading volume

Maravai's USD 2.54 to USD 9.42 52-week range places the October 16 price 167.32 percent above the low and 27.92 percent below the high. The stock's 1,579,688 shares traded were 50.30 percent below its 3,178,192-share average volume, both as of October 16, 2026. The latest price was also 3.96 percent below the previous Nasdaq session level of USD 7.07.

Valuation and November results

Maravai carried a market capitalization of USD 1.9 billion and a negative price-to-earnings ratio of 12.68 on October 16, 2026. The company is scheduled to hold its third-quarter 2026 earnings conference call on November 4, 2026 at 5:00 p.m. ET, according to its investor-relations calendar. That date gives the next major checkpoint for revenue, earnings and cash generation.

Comparison with peers

MRVI (Nasdaq, USD): minus 3.96 percent, P/E minus 12.68, market capitalization USD 1.9 billion.

CareDx (Nasdaq, USD): minus 4.01 percent, P/E 30.90, market capitalization USD 3.3 billion.

Atrium Therapeutics (Nasdaq, USD): minus 1.92 percent, P/E minus 1.99, market capitalization USD 131.2 million.

Price remains below the yearly high

The combination of a negative trailing valuation and a loss in the second quarter leaves the November earnings call as the next dated test for the business. The 52-week position also shows that the latest price remains well below the yearly high, despite the analyst target above the current quotation.

Maravai LifeSciences last traded at USD 6.79 on Nasdaq on October 16, 2026 at 4:00 p.m. ET, down 3.96 percent on the day. The further course of trading is shown by the continuously updated real-time quote of Maravai LifeSciences stock.